Cover Image

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and...

Full description

Saved in:
Bibliographic Details
Main Authors: Bachelot, Thomas (Author) , Schneeweiss, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 23 February 2019
In: Annals of oncology
Year: 2019, Volume: 30, Issue: 5, Pages: 766-773
ISSN:1569-8041
DOI:10.1093/annonc/mdz061
Online Access:Verlag, Volltext: https://doi.org/10.1093/annonc/mdz061
Verlag: https://academic.oup.com/annonc/article/30/5/766/5364015
Get full text
Author Notes:T. Bachelot, E. Ciruelos, A.Schneeweiss, F. Puglisi, T. Peretz-Yablonski, I. Bondarenko, S. Paluch-Shimon, A. Wardley, J. -L. Merot, Y. du Toit, V. Easton, N. Lindegger & D. Miles, on behalf of the PERUSE investigators

MARC

LEADER 00000caa a2200000 c 4500
001 1681605856
003 DE-627
005 20230426213255.0
007 cr uuu---uuuuu
008 191111s2019 xx |||||o 00| ||eng c
024 7 |a 10.1093/annonc/mdz061  |2 doi 
035 |a (DE-627)1681605856 
035 |a (DE-599)KXP1681605856 
035 |a (OCoLC)1341250622 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bachelot, Thomas  |e VerfasserIn  |0 (DE-588)1199320102  |0 (DE-627)1681615290  |4 aut 
245 1 0 |a Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)  |c T. Bachelot, E. Ciruelos, A.Schneeweiss, F. Puglisi, T. Peretz-Yablonski, I. Bondarenko, S. Paluch-Shimon, A. Wardley, J. -L. Merot, Y. du Toit, V. Easton, N. Lindegger & D. Miles, on behalf of the PERUSE investigators 
264 1 |c 23 February 2019 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.11.2019 
520 |a Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. Patients and methods: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). - Results: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nabpaclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months’ median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). - Conclusions: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. ClinicalTrials.gov: NCT01572038. 
700 1 |a Schneeweiss, Andreas  |d 1961-  |e VerfasserIn  |0 (DE-588)109972554  |0 (DE-627)632849630  |0 (DE-576)327251859  |4 aut 
773 0 8 |i Enthalten in  |t Annals of oncology  |d Amsterdam [u.a.] : Elsevier, 1990  |g 30(2019), 5, Seite 766-773  |h Online-Ressource  |w (DE-627)320428796  |w (DE-600)2003498-2  |w (DE-576)098134345  |x 1569-8041  |7 nnas  |a Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) 
773 1 8 |g volume:30  |g year:2019  |g number:5  |g pages:766-773  |g extent:8  |a Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) 
856 4 0 |u https://doi.org/10.1093/annonc/mdz061  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://academic.oup.com/annonc/article/30/5/766/5364015  |x Verlag 
951 |a AR 
992 |a 20191111 
993 |a Article 
994 |a 2019 
998 |g 109972554  |a Schneeweiss, Andreas  |m 109972554:Schneeweiss, Andreas  |d 910000  |d 910400  |e 910000PS109972554  |e 910400PS109972554  |k 0/910000/  |k 1/910000/910400/  |p 3 
999 |a KXP-PPN1681605856  |e 3538988870 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"id":{"issn":["1569-8041"],"zdb":["2003498-2"],"eki":["320428796"]},"recId":"320428796","pubHistory":["1.1990 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"issue":"5","year":"2019","pages":"766-773","volume":"30","text":"30(2019), 5, Seite 766-773","extent":"8"},"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"corporate":[{"role":"isb","display":"European Society for Medical Oncology","roleDisplay":"Herausgebendes Organ"}],"origin":[{"dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"disp":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Annals of oncology"}],"physDesc":[{"extent":"8 S."}],"note":["Gesehen am 11.11.2019"],"language":["eng"],"origin":[{"dateIssuedDisp":"23 February 2019","dateIssuedKey":"2019"}],"person":[{"family":"Bachelot","display":"Bachelot, Thomas","roleDisplay":"VerfasserIn","given":"Thomas","role":"aut"},{"role":"aut","family":"Schneeweiss","roleDisplay":"VerfasserIn","given":"Andreas","display":"Schneeweiss, Andreas"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)"}],"recId":"1681605856","id":{"eki":["1681605856"],"doi":["10.1093/annonc/mdz061"]},"name":{"displayForm":["T. Bachelot, E. Ciruelos, A.Schneeweiss, F. Puglisi, T. Peretz-Yablonski, I. Bondarenko, S. Paluch-Shimon, A. Wardley, J. -L. Merot, Y. du Toit, V. Easton, N. Lindegger & D. Miles, on behalf of the PERUSE investigators"]}} 
SRT |a BACHELOTTHPRELIMINAR2320 

Similar Items